Ascetic Soluble CD206 and Serum Interleukin-4 Can Predict Mortality in Acute Decompensated and Acute-on-Chronic Liver Failure

Aim. Acute-on-chronic liver failure (ACLF) is the most severe form of acute decompensation with intense systemic inflammation and immune dysfunction. IL-4 polarizes macrophages toward the M2 phenotype. CD206 can identify inflammatory peritoneal macrophages in cirrhotic patients and could be linked to prognosis in ACLF. We investigated the predictive value of serum IL-4 and ascitic soluble CD206 in patients with acute decompensation and ACLF and their relation to morbidity and early mortality.

Materials and methods. We included 60 patients with ACLF and acute decompensation as well as 30 cirrhotic controls. Clinical data were collected, and survival was followed for 1 and 3 months. Blood samples were analyzed at admission for liver and renal function tests as well as serum IL-4 and ascitic soluble CD206 levels. Correlation with liver function indicators and prognosis was assessed.

Results. IL-4 and CD206 were significantly higher in acute decompensation and ACLF patients compared to control and were positively correlated with each other’s Child — Pugh score, MELD-Na, and ACLF severity scores. Multivariate regression showed that baseline Child — Pugh score, ascitic soluble CD206, and serum IL-4 level are the only independent predictors of 1-month as well as 3-month mortality.

Conclusion. Serum IL-4 and ascitic soluble CD206 (macrophage markers) could predict early mortality in acute decompensation and ACLF. Incorporation of these markers into the traditional liver disease scores can improve their prognostic/predictive performance.

1. Schierwagen R., Gu W., Brieger A., Brüne B., Ciesek S., Đikić I., et al. Pathogenetic mechanisms and therapeutic approaches of acute-to-chronic liver failure. Am J Physiol Physiol. 2023;325(1):C129–40. DOI: 10.1152/ajpcell.00101.2023

2. Wong F. Innovative approaches to the management of ascites in cirrhosis. JHEP Rep. 2023;5(7):100749. DOI: 10.1016/j.jhepr.2023.100749

3. Wen Y., Lambrecht J., Ju C., Tacke F. Hepatic macrophages in liver homeostasis and diseases-diversity, plasticity and therapeutic opportunities. Cell Mol Immunol. 2021;18(1):45–56. DOI: 10.1038/s41423-020-00558-8

4. Wang C., Ma C., Gong L., Guo Y., Fu K., Zhang Y., et al. Macrophage polarization and its role in liver disease. Front Immunol. 2021;12:803037. DOI: 10.3389/fimmu.2021.803037

5. Stengel S., Quickert S., Lutz P., Ibidapo-Obe O., Steube A., Köse-Vogel N., et al. Peritoneal level of CD206 associates with mortality and an inflammatory macrophage phenotype in patients with decompensated cirrhosis and spontaneous bacterial peritonitis. Gastroenterology. 2020;158(6):1745– 61. DOI: 10.1053/j.gastro.2020.01.029

6. Lynch R., Hawley C., Bain C., Jenkins S. Role of exogenous interleukin 4 in the dynamics of acute liver injury. Lancet. 2017;389(Suppl 1):S64. DOI: 10.1016/S01406736(17)30460-9

7. Tsuchiya K., Suzuki Y., Yoshimura K., Yasui H., Karayama M., Hozumi H., et al. Author correction: Macrophage mannose receptor CD206 predicts prognosis in community-acquired pneumonia. Sci Rep. 2020;10(1):3324.

8. Nielsen M.C., Hvidbjerg Gantzel R., Clària J., Trebicka J., Møller H.J., Grønbæk H. Macrophage activation markers, CD163 and CD206, in acute-on-chronic liver failure. Cells. 2020;9(5):1175. DOI: 10.3390/cells9051175

9. Ossen L., Vesterhus M., Hov J.R., Färkkilä M., Rosenberg W.M., Møller H.J., et al. Circulating macrophage activation markers predict transplant-free survival in patients with primary sclerosing cholangitis. Clin Transl Gastroenterol. 2021;12(3):e00315. DOI: 10.14309/ctg.0000000000000315

10. El Ray A., Fouad R., ElMakhzangy H., El Beshlawy M., Moreau R., Sherbiny M. Characterizing a cohort of Egyptian patients with acute-on-chronic liver failure. Eur J Gastroenterol Hepatol. 2021;33(7):1023–8. DOI: 10.1097/MEG.0000000000002165

11. Zaccherini G., Weiss E., Moreau R. Acute-on-chronic liver failure: Definitions, pathophysiology and principles of treatment. JHEP Rep. 2020;3(1):100176. DOI: 10.1016/j.jhepr.2020.100176

12. Rashed E., Soldera J. CLIF-SOFA and CLIF-C scores for the prognostication of acute-on-chronic liver failure and acute decompensation of cirrhosis: A systematic review. World J Hepatol. 2022;14(12):2025–43. DOI: 10.4254/wjh.v14.i12.2025

13. Martin-Mateos R., Alvarez-Mon M., Albillos A. Dysfunctional immune response in acute-on-chronic liver failure: It takes two to tango. Front Immunol. 2019;10:973. DOI: 10.3389/fimmu.2019.00973

14. Chen S., Saeed A.F.U.H., Liu Q., Jiang Q., Xu H., Xiao G.G., et al. Macrophages in immunoregulation and therapeutics. Signal Transduct Target Ther. 2023;8(1):207. DOI: 10.1038/s41392-023-01452-1

15. Li L., Cheng Y., Emrich S., Schorey J. Activation of endothelial cells by extracellular vesicles derived from Mycobacterium tuberculosis-infected macrophages or mice. PLoS One. 2018;13(5):e0198337. DOI: 10.1371/journal.pone.0198337

16. Rødgaard-Hansen S., Rafique A., Christensen P.A., Maniecki M.B., Sandahl T.D., Nexø E., et al. A soluble form of the macrophage-related mannose receptor (MR/CD206) is present in human serum and elevated in critical illness. Clin Chem Lab Med. 2014;52(3):453–61. DOI: 10.1515/cclm-2013-0451

17. Grønbæk H., Gantzel R.H., Laursen T.L., Kazankov K., Møller H.J. Macrophage markers and innate immunity in cirrhosis. J Hepatol. 2020;73(6):1586–8. DOI: 10.1016/j.jhep.2020.07.033

18. Grønbæk H., Rødgaard-Hansen S., Aagaard N.K., Arroyo V., Moestrup S.K., Garcia E., et al.; CANONIC study investigators of the EASL-CLIF Consortium. Macrophage activation markers predict mortality in patients with liver cirrhosis without or with acute-on-chronic liver failure (ACLF). J Hepatol. 2016;64(4):813–22. DOI: 10.1016/j.jhep.2015.11.021

19. Khorami S.H.H., Nejatollahi F., Davarpanah M.A. Serum levels of interleukin-4, interleukin-10 and interferon-γ in patients with chronic hepatitis B infection. Hepat Mon. 2018;18(4):e60377. DOI: 10.5812/hepatmon.60377

20. Rainer F., Horvath A., Sandahl T.D., Leber B., Schmerboeck B., Blesl A, et al. Soluble CD163 and soluble mannose receptors predict survival and decompensation in patients with liver cirrhosis and correlate with gut permeability and bacterial translocation. Aliment Pharmacol Ther. 2018;47(5):657–64. DOI: 10.1111/apt.14474

21. Orntoft N.W., Blé M., Baiges A., Ferrusquia J., Hernández-Gea V., Turon F., et al. Divergences in macrophage activation markers soluble CD163 and mannose receptor in patients with non-cirrhotic and cirrhotic portal hypertension. Front Physiol. 2021;12:649668. DOI: 10.3389/fphys.2021.649668

22. Li T.P., Guan S.H., Wang Q., Chen L.W., Yang K., Zhang H. Soluble mannose receptor as a predictor of prognosis of hepatitis B virus-related acute-on-chronic liver failure. World J Gastroenterol. 2019;25(37):5667–75. DOI: 10.3748/wjg.v25.i37.5667

23. van der Zande H.J.P., Nitsche D., Schlautmann L., Guigas B., Burgdorf S. The mannose receptor: From endocytic receptor and biomarker to regulator of (meta)inflammation. Front Immunol. 2021;12:765034. DOI: 10.3389/fimmu.2021.765034

24. Nielsen M.C., Hvidbjerg Gantzel R., Clària J., Trebicka J., Møller H.J., Grønbæk H. Macrophage activation markers, CD163 and CD206, in acute-on-chronic liver failure. Cells. 2020;9(5):1175. DOI: 10.3390/cells9051175

25. Ahmed A.M.M., Kadaru A.G.Y., Omer I., Musa A.M., Enan K., El Khidir I.M., et al. Macrophages from patients with cirrhotic ascites showed function alteration of host defense receptor. J Clin Exp Hepatol. 2014;4(4):279–86. DOI: 10.1016/j.jceh.2014.08.003

26. Tan-Garcia A., Lai F. Irac S.E., Ng P.Y., Msallam R., et al. Liver fibrosis and CD206+ macrophage accumulation are suppressed by anti-GM-CSF therapy. JHEP Reports. 2020;2(1):100062. DOI: 10.1016/j.jhepr.2019.11.006

27. Dang B., Gao Q., Zhang L., Zhang J., Cai H., Zhu Y., et al. The glycolysis/HIF-1α axis defines the inflammatory role of IL-4-primed macrophages. Cell Rep. 2023;42(5):112471. DOI: 10.1016/j.celrep.2023.112471

28. Li L., Chen L., Lin F., Mu J., Wang D., Zhang W., et al. Study of the expression of inflammatory factors IL-4, IL-6, IL-10, and IL-17 in liver failure complicated by coagulation dysfunction and sepsis. J Inflamm Res. 2021;14:1447–53. DOI: 10.2147/JIR.S302975

29. Cheng Y., Tian Y., Xia J., Wu X., Yang Y., Li X., et al. The role of PTEN in the regulation of hepatic macrophage activation and function in the progression and reversal of liver fibrosis. Toxicol Appl Pharmacol. 2017;317:51–62. DOI: 10.1016/j.taap.2017.01.005

30. Weiss E., de la Grange P., Defaye M., Lozano J.J., Aguilar F., Hegde P., et al. Characterization of blood immune cells in patients with decompensated cirrhosis including ACLF. Front Immunol. 2021;11:619039. DOI: 10.3389/fimmu.2020.619039